TY - JOUR T1 - Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC JF - Anticancer Research JO - Anticancer Res SP - 2241 LP - 2247 DO - 10.21873/anticanres.15704 VL - 42 IS - 5 AU - MARIA BASSANELLI AU - SARA RAMELLA AU - MASSIMO ZEULI AU - ANNA CERIBELLI Y1 - 2022/05/01 UR - http://ar.iiarjournals.org/content/42/5/2241.abstract N2 - Immune checkpoint inhibitors (ICPi) targeting programmed cell death 1(PD-1)/programmed cell death ligand-1 (PD-L1) have revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC). Despite impressive success, only a small proportion of patients benefit from PD1/PDL1 inhibitors. Radiotherapy (RT) can induce a systemic anti-tumor immune response on local and distant tumors. Some preclinical and clinical evidence showed a critical role of RT to overcome acquired resistance to immunotherapy. Currently, durvalumab consolidation represents the new standard treatment for unresectable stage III NSCLC patients whose tumors express PDL1 on ≥1% of tumor cells (TC), and whose disease has not progressed following platinum-based chemoradiotherapy (CRT). In this review, we focus on the synergic effect of RT with ICPi and the new role that different RT schedules can play in combination with immunotherapy for early-stage NSCLC. ER -